Insulin Induces Outer Blood–Retinal Barrier Disruption via Downregulation of Claudin-19
Investigative Ophthalmology & Visual Science · 2026
DOI: 10.1167/iovs.67.4.39 ↗At a glance
Journal article in Investigative Ophthalmology & Visual Science, 2026. Written by Karen R Hernandez and 5 co-authors. Institution: Department of Pharmacology, Case Western Reserve University, Cleveland, Ohio, United States. Major MEDLINE topics: Blood-Retinal Barrier, Insulin, Claudins, Retinal Pigment Epithelium. Cited 1 times so far (Crossref); 51 references. The full text is freely available (open access, CC BY 4.0). Funded by: NINDS NIH HHS.
Abstract (original language)
Purpose
Diabetic retinopathy is a common complication of diabetes mellitus, a disease that is reaching epidemic proportions worldwide. Although diabetic macular edema has generally been attributed to breakdown of the inner blood-retinal barrier, accumulating evidence suggests that the outer blood-retinal barrier (oBRB) may also be involved. Clinical studies have shown that acute intensive insulin therapy causes a transient worsening of diabetic retinopathy in type 1 and type 2 diabetes. In this study, we tested the hypothesis that insulin directly disrupts the oBRB by targeting claudin-19 tight junctions in the retinal pigment epithelium (RPE).
Methods
The effects of insulin on claudin-19 tight junctions in primary RPE cells were assessed by immunohistochemistry and western blot analysis using in vitro cell culture models and an in vivo transgenic zebrafish model. Changes in blood-retinal barrier integrity were quantified using electric cell-substrate impedance sensing (ECIS).
Results
Claudin-19 was identified as the predominant claudin in primary porcine RPE cells and was essential for maintaining oBRB integrity. Barrier function did not differ between RPE cells cultured under physiological (5 mM) or high (25 mM; diabetic) glucose conditions. In contrast, insulin treatment disrupted the oBRB independently of glucose concentration. Insulin significantly reduced claudin-19 protein levels without affecting transcript abundance, indicating post-transcriptional regulation. Consistent with the in vitro findings, insulin induced claudin-19 tight junction disruption in vivo in a transgenic zebrafish model expressing claudin-19 fused to enhanced green fluorescent protein. Consistent with the in vitro findings, high glucose alone did not disrupt claudin-19 in vivo.
Conclusions
These findings demonstrate that insulin disrupts the oBRB independently of glucose concentration in both in vitro and in vivo models. This work provides new insight into the molecular mechanisms underlying early worsening of diabetic retinopathy and highlights a potential role for hyperinsulinemia in type 2 diabetes-associated retinal pathology.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Pharmacology, Case Western Reserve University, Cleveland, Ohio, United States.
- Department of Ophthalmic Research, Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio, United States.
- Department of Neurosciences, Cleveland Clinic Foundation, Cleveland, Ohio, United States.
Funding
- NINDS NIH HHS
Cite
APA
Hernandez, K. R., Pollock, L. M., Rodriguez, A. D., Lohr, M. F., Matsuoka, R. L., & Anand-Apte, B. (2026). Insulin Induces Outer Blood–Retinal Barrier Disruption via Downregulation of Claudin-19. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.67.4.39
Vancouver
Hernandez KR, Pollock LM, Rodriguez AD, Lohr MF, Matsuoka RL, Anand-Apte B. Insulin Induces Outer Blood–Retinal Barrier Disruption via Downregulation of Claudin-19. Investigative Ophthalmology & Visual Science. 2026. doi:10.1167/iovs.67.4.39
BibTeX
@article{Hernandez2026,
author = {Hernandez, Karen R and Pollock, Lana M and Rodriguez, Aidan D and Lohr, M F and Matsuoka, Ryota L and Anand-Apte, Bela},
title = {Insulin Induces Outer Blood–Retinal Barrier Disruption via Downregulation of Claudin-19},
journal = {Investigative Ophthalmology & Visual Science},
year = {2026},
doi = {10.1167/iovs.67.4.39}
}
EUVIMED